Long-Term Survival After Initial Invasive or Conservative Management of Stable Coronary Disease in ISCHEMIA-EXTEND.

It is unknown whether routine invasive management of chronic coronary disease improves long-term survival when added to guideline-directed medical therapy. To compare the effects of initial invasive and conservative strategies on long-term mortality in patients with chronic coronary disease. In this long-term follow-up study of the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA), an international trial of patients with chronic coronary dise
It is unknown whether routine invasive management of chronic coronary disease improves long-term survival when added to guideline-directed medical therapy. To compare the effects of initial invasive and conservative strategies on long-term mortality in patients with chronic coronary disease. In this long-term follow-up study of the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA), an international trial of patients with chronic coronary disease, moderate or severe ischemia, left ventricular ejection fraction of 35% or more, and no left main coronary artery disease, unacceptable angina, or recent acute coronary syndrome, participants were randomized at 320 sites in 37 countries beginning August 2012 and followed up through December 2025. Data were analyzed using the intention-to-treat principle. ISCHEMIA randomized patients to an initial invasive strategy of guideline-directed medical therapy plus coronary angiography and revascularization (when feasible) or an initial conservative strategy with guideline-directed medical therapy alone, with invasive management for failure of medical therapy. All-cause, cardiovascular, and noncardiovascular mortality were analyzed using cumulative incidence estimates, Cox and Fine-Gray models, bayesian analysis, and restricted mean survival time. Among 5179 participants, median age was 64 (IQR, 58-70) years; 23% were female, 42% had diabetes, and median ejection fraction was 60% (IQR, 55%-65%). During 9-year median follow-up (range, 1 day to 13.4 years), 1071 deaths occurred (782 during extended follow-up): 672 cardiovascular, 359 noncardiovascular, and 40 unclassified. All-cause 11-year mortality was not significantly different between groups (25.8% invasive vs 26.9% conservative; estimated difference, -1.0 percentage point [95% CI, -4.2 to 2.1 percentage points]; adjusted hazard ratio [AHR], 0.97 [95% CI, 0.86-1.09]). By bayesian analysis, the posterior probability of more than 1 percentage-point survival benefit to invasive vs conservative was low (18%). Cardiovascular mortality at 11 years was 15.8% in the invasive group vs 17.1% in the conservative group (estimated difference, -1.4 percentage points [95% CI, -4.0 to 1.3 percentage points]; AHR, 0.88 [95% CI, 0.75-1.02]). Noncardiovascular mortality at 11 years was 9.1% in the invasive group vs 8.1% in the conservative group (estimated difference, 1.0 percentage point [95% CI, -0.9 to 2.9 percentage points]; AHR, 1.18 [95% CI, 0.96-1.45]). Eleven-year restricted mean survival was not significantly different (estimated difference, 14 days [95% CI, -41 to 70 days]). In this study, long-term all-cause mortality in patients with high-risk chronic coronary disease was not significantly different after routine invasive vs initial conservative management. ClinicalTrials.gov Identifier: NCT04894877.




